BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

Ginkgo financing to support COVID-19 testing  New investor Illumina Inc. (NASDAQ:ILMN) led a $70 million round on Thursday for genetic engineering company Ginkgo Bioworks Inc.; existing investors General Atlantic and Viking Global Investors also participated....
BioCentury | May 18, 2020
Finance

$65M round positions SQZ Biotech for potential IPO, 2021 catalysts

SQZ Biotech is adding at least one experienced crossover investor to what could be its last private financing ahead of catalysts expected late this year and next. SQZ Biotechnologies Co. raised $65 million in a...
BioCentury | May 14, 2020
Management Tracks

Jakob Dupont steps down as CMO of Gossamer; plus Ascendis, Seer, Jazz, Dragonfly and more

Immunology, inflammation and oncology company Gossamer Bio Inc. (NASDAQ:GOSS) said CMO Jakob Dupont has stepped down. CEO Sheila Gujrathi will take on the role’s responsibilities; the biotech told BioCentury there are no plans to immediately...
BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

New round pushes Grail’s venture tally over $1.9B Grail Inc. raised $390 million in a series D round, marking the year's largest venture round to date. New backers, including Public Sector Pension Investment Board and...
BioCentury | May 6, 2020
Management Tracks

Mendel named GenMark’s CEO; plus SutroVax, Illumina, Arrowhead, Tessa and more

GenMark Diagnostics Inc. (NASDAQ:GNMK) said interim president and CEO Scott Mendel will now serve in those roles full-time. He joined the company as CFO in 2014 and became COO in 2019. The diagnostic company’s PCR-based...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

Fibrosis company Avalyn raises $35.5M series B  Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with...
BioCentury | Mar 25, 2020
Product Development

‘Diversified’ gut-brain axis company Kallyope heading to clinic with $112M series C

With what CEO Nancy Thornberry described as a breadth of options spanning multiple therapeutic areas, gut-brain axis company Kallyope will use its new $112 million series C round to bring its first two small molecule...
BioCentury | Mar 24, 2020
Product Development

March 23 COVID-19 roundup: Gilead looks to expand access to remdesivir, antiviral gains Orphan designation; plus N.Y.’s chloroquine trial, Celltrion and more

As Gilead begins shifting its individual compassionate use authorizations for COVID-19 candidate remdesivir to broader expanded access programs, the antiviral was granted Orphan Drug designation Monday. The day also saw several companies begin work on...
BioCentury | Mar 19, 2020
Politics, Policy & Law

Former FDA Commissioners Gottlieb and McClellan propose actions to speed COVID-19 countermeasures

FDA should create task forces to facilitate the rapid development of point-of-care diagnostics, therapeutics and prophylactics for COVID-19, former FDA Commissioners Scott Gottlieb and Mark McClellan recommended in a working paper released Thursday. They also...
Items per page:
1 - 10 of 800
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

Ginkgo financing to support COVID-19 testing  New investor Illumina Inc. (NASDAQ:ILMN) led a $70 million round on Thursday for genetic engineering company Ginkgo Bioworks Inc.; existing investors General Atlantic and Viking Global Investors also participated....
BioCentury | May 18, 2020
Finance

$65M round positions SQZ Biotech for potential IPO, 2021 catalysts

SQZ Biotech is adding at least one experienced crossover investor to what could be its last private financing ahead of catalysts expected late this year and next. SQZ Biotechnologies Co. raised $65 million in a...
BioCentury | May 14, 2020
Management Tracks

Jakob Dupont steps down as CMO of Gossamer; plus Ascendis, Seer, Jazz, Dragonfly and more

Immunology, inflammation and oncology company Gossamer Bio Inc. (NASDAQ:GOSS) said CMO Jakob Dupont has stepped down. CEO Sheila Gujrathi will take on the role’s responsibilities; the biotech told BioCentury there are no plans to immediately...
BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

New round pushes Grail’s venture tally over $1.9B Grail Inc. raised $390 million in a series D round, marking the year's largest venture round to date. New backers, including Public Sector Pension Investment Board and...
BioCentury | May 6, 2020
Management Tracks

Mendel named GenMark’s CEO; plus SutroVax, Illumina, Arrowhead, Tessa and more

GenMark Diagnostics Inc. (NASDAQ:GNMK) said interim president and CEO Scott Mendel will now serve in those roles full-time. He joined the company as CFO in 2014 and became COO in 2019. The diagnostic company’s PCR-based...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

Fibrosis company Avalyn raises $35.5M series B  Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with...
BioCentury | Mar 25, 2020
Product Development

‘Diversified’ gut-brain axis company Kallyope heading to clinic with $112M series C

With what CEO Nancy Thornberry described as a breadth of options spanning multiple therapeutic areas, gut-brain axis company Kallyope will use its new $112 million series C round to bring its first two small molecule...
BioCentury | Mar 24, 2020
Product Development

March 23 COVID-19 roundup: Gilead looks to expand access to remdesivir, antiviral gains Orphan designation; plus N.Y.’s chloroquine trial, Celltrion and more

As Gilead begins shifting its individual compassionate use authorizations for COVID-19 candidate remdesivir to broader expanded access programs, the antiviral was granted Orphan Drug designation Monday. The day also saw several companies begin work on...
BioCentury | Mar 19, 2020
Politics, Policy & Law

Former FDA Commissioners Gottlieb and McClellan propose actions to speed COVID-19 countermeasures

FDA should create task forces to facilitate the rapid development of point-of-care diagnostics, therapeutics and prophylactics for COVID-19, former FDA Commissioners Scott Gottlieb and Mark McClellan recommended in a working paper released Thursday. They also...
Items per page:
1 - 10 of 800